Venous thromboembolic disease

Slides:



Advertisements
Similar presentations
Viral vents his frustration with.  What the d-dimer actually measures  Usual applications of d-dimer  Interesting applications of d-dimer  How to.
Advertisements

Venous Thromboembolism: Risk Assessment and Prophylaxis
Heparin Resistance “Heparin resistance is a term used to describe the situation when patients require unusually high doses of heparin to achieve a therapeutic.
Indications for a thrombophilia workup in Obstetrics Helen H. Kay, MD February, 2005.
1 THROMBOPHILIA. 2 Thrombophilia is technical term for hypercoagulable state Thrombosis (arterial or venous) is produced by a shift in the balance between.
Thrombophilia. Now considered a multicausal disease, with an interplay of acquired and genetic thrombotic risk factors Approximately half of venous thromboembolic.
Pathology of Coagulation I- Deficiency of Coagulation Factors II- II- HYPERCOAGULABLE STATES.
Thrombophilic states. Thrombophilic state is characterized by a shift in the coagulation balance in favour of hypercoagulability – i.e. easier and oftener.
Pathology 430/826 Thrombosis David Lillicrap. Cardiovascular Disease 30% of all deaths in Canada 54% ischemic heart disease 20% stroke 23% heart attack.
The DASH Study Patrick Leonberger MSIV BGSMC Nov 8, 2013.
Factor V Leiden Developed by Dr. Judith Allanson, Ms. Shawna Morrison and Dr. June Carroll Last updated Dec 2014.
Below the Knee DVT and Pregnancy Related Thrombosis Robert Lampman, MD Morning Report July 2009.
Week 7: Fibrinolysis and Thrombophilia Secondary fibrinolysis Secondary fibrinolysis Primary fibrinolysis Primary fibrinolysis Plasminogen Plasminogen.
Venous thromboembolism: how long to treat?
ESTROGENS AND CARDIOVASCULAR DISEASES
Volume 359: November 6, 2008 Number 19November 6, 2008.
Thrombophilia For the Clinician
Thrombophilias Sharon Sams. Objectives Overview of etiology of hypercoagulability Available tests Clinical correlation or “What do I do with these results?”
PATHOPHYSIOLOGY OF THROMBOSIS “Virchow’s Triad” 1.Injury to blood vessels Trauma, atherosclerosis, surgery 2.Stasis of blood Immobility, venous incompetence,
Dr Nico Lategan MBChB, MMed (Haematology)
Hypercoagulable States Basic Clinician Training Module 4 Introduction Hypercoagulable States Test Your Knowledge.
Extended Anticoagulation in VTE Geoffrey Barnes, MD Cardiovascular and Vascular Medicine University of Michigan, USA 1 st Qatar Conference on Safe Anticoagulation.
Epidemiology and diagnosis of acute pulmonary embolism Dr Sam Z Goldhaber Associate Professor of Medicine Harvard Medical School Staff Cardiologist Brigham.
Chapter Ten Venous Disease Coalition Hypercoagulability VTE Toolkit.
Management thrombophilia. introduction Twenty percent of maternal deaths in the United States during that period were attributed to PE. Inherited thrombophilias.
Thrombophilia— Hypercoagulable States Gabriel Shapiro, MD, FACP.
Bob Silver, MD University of Utah Health Sciences Thrombophilias in Obstetrics Modified from a presentation to the Society of Maternal Fetal Medicine by.
HEMOSTASIS/THROMBOSIS III Regulation of Coagulation/Disseminated Intravascular Coagulation.
Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.
Chapter 34 Vascular Thrombosis Due to Hypercoagulable States
Diane 35 safety concerns BY: MOHAMMED ALSAIDAN.
APPROACH TO BLEEDING DISORDERS. History of Bleeding Spontaneous vs. trauma/surgery-induced Ecchymoses without known trauma Medications or nutritional.
Coagulation Concepts A review of hemostasis Answers are in the notes pages.
Thrombophilia (Hypercoagulable States)
Hormone Therapy for Menopause: Current Data Jan Shepherd, MD, FACOG.
Hypercoagulable Syndromes. Risk Factors For Venous Thrombosis ACQUIREDINHERITEDMIXED/UNKNOWN Advancing ageAntithrombin Deficiency  Homocysteine ObesityProtein.
Understanding the scientific literature (Reading and evaluation of a research paper) Prof David Lane Department of Haematology Hammersmith Hospital Campus.
Pulmonary Embolism Treatment in Cancer - Is It Different 34th Brazilian Thoracic Conference 6th ALAT Congress 5th Brazil-Portugal Congress Brazilia/DF.
Tabuk University Faculty of Applied Medical Sciences Department Of Medical Lab. Technology 3 rd Year – Level 5 – AY
Obesity and Venous Thromboembolic Disease Angel Galvez MD PhD Oncology Specialists SC Lutheran General Hospital.
Thrombophilia National Haemophilia Director
Antiplatelet Therapy Use and the Risk of Venous Thromboembolic Events in the Double-Blind Raloxifene Use for the Heart (RUTH) Trial C. Duvernoy 1, A. Yeo.
Hypercoagulable States. Acquired versus inherited Acquired versus inherited “Provoked” vs idiopathic VTE “Provoked” vs idiopathic VTE Who should be tested.
Thrombophilia (Hypercoagulable States) Abdulkareem Almomen, MD Professor of Medicine & Hematology, King Saud University MED 341, Feb.2014.
Thrombophilia. Definition –Tendency to develop clots due to predisposing factors that may be genetically determined.
Charles J. Lockwood, M.D. The Anita O’Keefe Young Professor and Chair Department of Obstetrics, Gynecology and Reproductive Sciences Yale University School.
The Clotting Cascade and DIC Karim Rafaat, MD. Coagulation Coagulation is a host defense system that maintains the integrity of the high pressure closed.
Stroke John C. Stevenson Editor: Martin Birkhäuser.
Beginning of the chapter Thrombosis and genetics (Thrombo Sensor) 36.
Menopausal Hormone Replacement Professor Gordana Prelevic, MD, DSc, FRCP Consultant Endocrinologist Royal Free Hampstead NHS Trust Whittington Health.
Protein C.  Protein C is a major physiological anticoagulant. anticoagulant  It is a vitamin K-dependent serine protease enzyme, that is activated by.
Mechanism of Action of Aspirin Carlo Patrono, et al, N Engl J Med 2005;353:
LABORATORY DIAGNOSIS OF PROTHROMBOTIC STATES. REGULATION OF COAGULATION Introduction Coagulation necessary for maintenance of vascular integrity Enough.
Thrombophilia Made Simple for Obstetricians
Management issues in other thrombophilia Ng Heng Joo Department of Haematology Singapore General Hospital.
1 Risk Benefit and Conclusions George Sledge, MD Indiana University School of Medicine.
Hypercoagulable States
Women’s Issues and Blood Clotting
Deficiencies of Proteins C, S and Antithrombin and Activated Protein C Resistance – Their Involvement in the Occurrence of Arterial Thromboses Report PGY.
Member of the Executive Board of EBCOG
Venous Thromboembolism Prophylaxis for Medical Inpatients
Thrombosis.
Venous Thromboembolic Disease
Hypercoagulable States
Dr Ferdous Mehrabian. Dr Ferdous Mehrabian Inherited thrombophilias in pregnancy Inherited thrombophilias is a genetic tendency to venous thrombosis.
Impact of Oestrogen Therapy on Diabetes and Vascular Risk
Fellowship of infertility
Thrombophilia.
Cardiovascular Disease in Women Module VI: Update on Menopausal Hormone Therapy and Selective Estrogen Receptor Modulators (SERMs) This slide set was.
Hemostasis Hemostasis depends on the integrity of Blood vessels
Presentation transcript:

Venous thromboembolic disease John C. Stevenson Editor: Martin Birkhäuser

Coagulation and fibrinolysis Endothelial cells Activated platelets XII TFPI tPA PAI-1 IX Protein C Protein S VIII VII X TF Plasminogen V AT Prothrombin F1+2 Plasmin Thrombin FPA Fibrinogen Fibrin D-dimer

Venous thromboembolism Risk of VTE in postmenopausal women: 1 per 10,000 patient-years 2–3 non-fatal VTE per year for every 10,000 women given HRT Deaths from VTE: 1 per 1,000,000 patient-years

Increased VTE risk Age Obesity Malignancy Immobilization History/family history Oral estrogen Specific SERMs

Venous thromboembolism HRT affects vascular endothelium Oral HRT affects hepatic production and clearance of hemostatic factors

Oral HRT and VTE Observational studies Case-control studies (n = 7) RR 2.1 (CI 1.4–3.0) Prospective cohort studies (n = 1) RR 2.1 (CI 1.2–3.8) Oger and Scarabin. Drugs Aging 1999;14:55–61

Oral HRT and VTE Randomized clinical trials HERS RR 2.9 (CI 1.5–5.6) WHI (E alone) RR 1.3 (CI 1.0–1.8) WHI (E + P) RR 2.1 (CI 1.6–2.7) E + P (age 70–79 years) RR 7.5 vs. placebo (age 50–59 years) E + P (age 50–59 years) RR 0.7 vs. placebo (age 70–79 years) Hulley et al. J Am Med Assoc 1998;280:605–13 Cushman et al. J Am Med Assoc 2004;292:1573–80 Women’s Health Initiative Steering Committee. J Am Med Assoc 2004;291:1701–12

ERT/HRT and thromboembolic risk: absolute risk A per oral HRT increases moderately the thromboembolic risk, in particular in presence of hereditary or acquired thrombophilia, and during the first year after initiation of ERT/HRT (Age 50–59: 2 additional cases/year per 10,000 women) Low-dose transdermal HRT seems not to increase the thromboembolic risk WHI, Cushman M, et al. J Am Med Assoc 2004;292:1573–80

Oral HRT and VTE Duration and dose of HRT Risk of VTE higher in first year of treatment Risk of VTE dose-dependent Effect of HRT less than OC in women with other increased VTE risk <1 year Duration >1 year High Dose Low 2 4 6 8 Odds ratio Oger and Scarabin. Drugs Aging 1999;14:55–61 Waselenko et al. Semin Thromb Hemost 1998;24(Suppl):33–9

HRT route and VTE No HRT Transdermal HRT Oral HRT 2 4 6 8 Odds ratio 2 4 6 8 Odds ratio Scarabin, et al. Lancet 2003;362:428–32

Risk of VTE: HRT route of administration and progestogens (ESTHER study) Route/progestagen OR 95% CI Oral 4.2 1.5–11.6 Transdermal 0.9 0.4–2.1 Micronized progesterone 0.7 0.3–1.9 Pregnanes 0.9 0.4–2.3 Norpregnanes 3.9 1.5–10.0 Canonico M, et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Circulation 2007;115:820–2

SERMS and VTE Randomized clinical trials Tamoxifen (n = 5408) RR 1.63 (CI 1.02–2.63) Raloxifene (n = 10,101) RR 1.44 (CI 1.06–1.85) Decensi, et al. Circulation 2005;111:650–56 Barrett-Connor, et al. N Engl J Med 2006;355:125–37

Thrombophilia Established inherited Antithrombin deficiency Protein C deficiency Protein S deficiency Activated protein C resistance (factor V Leiden) Homocystinuria Dysfibrinogenemia Prothrombin gene mutation Further Homocystinuria Factor VIII elevation Low tissue factor pathway inhibitor (TFPI)

Protein C anticoagulant pathway PC PS Va T PC APC VIIIa T PS Va VIIIa APC Thrombomodulin APC receptor VIIIa inactive Va inactive Dahlback B. Thromb Res 1995;77:1–43

HRT route and ETP-APC resistance 152 hysterectomized, postmenopausal women Aged 45–65 years Randomized to placebo, transdermal estradiol 50 μg, oral estradiol 1 mg, oral estradiol 1 mg + gestodene 25 μg for 13 cycles Normalized ETP-APC sensitivity ratios measured * * *p < 0.001 vs. placebo Post, et al. Arterioscler Thromb Vasc Biol 2003;23:1116–21

HRT and prothrombotic mutations 235 postmenopausal women with VTE 22% oral E 26% transdermal E 554 postmenopausal controls 7% oral E 31% transdermal E 4.9% prevalence of factor V Leiden 2.5% prevalence of prothrombin G20210A mutation Straczek, et al. Circulation 2005;112:3495–500

Acquired ETP-APC resistance Antiphospholipid syndrome Oral contraception Pregnancy Oral estrogen (CEE and E2) replacement

Thrombophilia screening Patients with personal history of VTE Patients with first- or second-degree relative with VTE

VTE management Full anti-coagulation Low-dose warfarin (1 mg/day) lifelong Low-dose aspirin lifelong Avoidance of oral HRT (CEE, E2, tamoxifen, raloxifene)

HRT and thromboembolism IMS UPDATED RECOMMENDATIONS ON POSTMENOPAUSAL HORMONE THERAPY HRT and thromboembolism The HRT-related risk for serious venous thromboembolic events increases with age (although minimal until age 60) and is also positively associated with obesity and thrombophilia By avoiding first-pass hepatic metabolism, transdermal estrogen may avert the risk associated with oral HRT The impact on the risk of a thromboembolic event may also be affected by progestogen, depending on the type Climacteric 2007;10:181–96

HRT and thromboembolism: Misperceptions The risk of both venous and arterial thromboembolism is increased during HRT Stroke risk is substantially increased in women receiving HRT IMS Global Summit 2008. Climacteric 2008;11:267–72

HRT and thromboembolism: Evidence The risk of venous thrombosis is approximately two-fold higher with standard doses of oral HRT, but is a rare event in that the background prevalence is extremely low in a healthy woman under 60 years of age. It is also associated with obesity and with thrombophilia The risk of venous thrombosis is possibly less with transdermal, compared with oral, estrogen therapy IMS Global Summit 2008. Climacteric 2008;11:267–72